Shopping Cart
Remove All
Your shopping cart is currently empty
Cefpodoxime proxetil
Copy Product Info
🥰Excellent
Catalog No. T4998Cas No. 87239-81-4
Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
Cefpodoxime proxetil
Copy Product Info🥰Excellent
Purity: 99.81%
Catalog No. T4998Cas No. 87239-81-4
Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime.
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 25 mg | $40 | In Stock | In Stock | |
| 50 mg | $60 | In Stock | In Stock | |
| 100 mg | $89 | In Stock | In Stock | |
| 500 mg | $176 | In Stock | In Stock | |
| 1 mL x 10 mM (in DMSO) | $29 | In Stock | In Stock |
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Batch Information
Select Batch
Purity:99.81%
Color:White
Contact us for more batch information
Resource Download
Product Introduction
Cefpodoxime proxetil AI Summary
Cefpodoxime proxetil exhibits various bioactivities across a range of biological targets and systems. It shows cytotoxicity to Streptococcus (EC50 = 987.0 nM), SK(-)GAS Group A Streptococcus (EC50 = 697.0 nM), and inhibits Streptokinase Promotor Activity (EC50 = 797.0 nM). It induces DNA re-replication in MCF 10a normal breast cells (6513.1 nM potency) and inhibits Hepatitis C Virus (EC50 = 891.3 nM). Additionally, it targets human tyrosyl-DNA phosphodiesterase 1 (TDP1) and exhibits antimalarial potential against AMA1-RON (11220.2 nM). Cefpodoxime proxetil also demonstrates activity against Lassa Virus, Marburg Virus (7943.3 nM), and blocks Ebola Virus entry.
In human assays, Cefpodoxime proxetil suggests moderate intestinal absorption with a log10(%HIA+10) value of 1.778. It shows potential hepatotoxicity, indicated by elevated serum levels of liver enzymes (ALT, AST, SGOT, SGPT) and a moderate hepatotoxicity rate of 7.1% in clinical trials. However, it does not induce severe acute liver toxicity or chronic liver diseases.
Pharmacokinetics studies reveal an intrinsic clearance of 114.82 uL.min-1.(10^6cells)-1 in rat hepatocytes and >150.0 mL.min-1.g-1 in human liver microsomes. It inhibits human BSEP (IC50 = 81700.0 nM) and other MRP proteins with IC50 values above 133000.0 nM. Administered orally (100-400 mg twice daily), it achieves an AUC of 12300.88 ng.hr.mL-1 and a Css of 1.838 uM in humans.
Antiviral activities include inhibition of SARS-CoV-2 induced cytotoxicity in Caco-2 cells (4.86% inhibition at 10 uM) and Vero E6 cells (IC50 > 20000 nM). However, it shows lower activity in these assays under specific conditions. Additionally, Cefpodoxime proxetil has limited antifungal activity against Candida albicans and Cryptococcus neoformans and moderate antibacterial effects against several strains, though showing variable effectiveness against MRSA.
Moreover, Cefpodoxime proxetil shows weak inhibitory activity on SARS-CoV-2 3CL-Pro protease and HDAC6 enzyme in various assays. Based on data, it does not exhibit significant binding affinity or activity in other receptor and enzyme in vitro assays, further indicating a broad but moderate bioactivity profile..
Note: Summary generated by AI. Data source: ChEMBL 
Bioactivity
Chemical Properties
Storage & Solubility Information
| Description | Cefpodoxime is an oral third generation cephalosporin antibiotic. It is active against most Gram positive and Gram negative bacteria. It is commonly used to treat acute otitis media, pharyngitis, and sinusitis. Cefpodoxime proxetil is a prodrug which is absorbed and de-esterified by the intestinal mucosa to Cefpodoxime. |
| Molecular Weight | 557.6 |
| Formula | C21H27N5O9S2 |
| Cas No. | 87239-81-4 |
| Smiles | C(OC(OC(OC(C)C)=O)C)(=O)C=1N2[C@@]([C@H](NC(/C(=N\OC)/C=3N=C(N)SC3)=O)C2=O)(SCC1COC)[H] |
| Relative Density. | 1.58 g/cm3 (Predicted) |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (80.7 mM), Sonication is recommended.  | ||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.59 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | ||||||||||||||||||||||||||||||
Solution Preparation Table | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, and a total of 10 animals are to be administered, using a formulation of 
10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.Stock Solution Preparation:
Dissolve 2 mg of the compound in 100 μL DMSO to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
Preparation of the In Vivo Formulation:
1) Add 100 μL of the DMSO stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O and mix thoroughly until a homogeneous solution is obtained.
This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy Cefpodoxime proxetil | purchase Cefpodoxime proxetil | Cefpodoxime proxetil cost | order Cefpodoxime proxetil | Cefpodoxime proxetil chemical structure | Cefpodoxime proxetil formula | Cefpodoxime proxetil molecular weight
Generate Quote
Catalog No.: Cas No.:
Add
| Size | Quantity | Unit Price | Amount | Operation |
|---|
Generate Quote
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.